Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 147 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Adagrasib Shows Clinical Efficacy in Patients with Previously Treated KRASG12C-Mutated Advanced... June 9, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Futibatinib April 28, 2023 Blood Test Accurately Detects Early-Stage Pancreatic Cancer May 10, 2024 Cancer Won’t Wait: “I prayed she would see her daughter start... October 11, 2021 Load more HOT NEWS Grief Anniversaries Efficacy of Dabrafenib Plus Trametinib in First-Line Treatment for Children and... Cancer in My Community: Developing Pediatric Palliative and Supportive Care in... FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute...
